We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

1 hedge funds and large institutions have $0 invested in Acceleron Pharma in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 325 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 330 → 1 (-329)

100% less funds holding in top 10

Funds holding in top 10: 13 → 0 (-13)

100% less capital invested

Capital invested by funds: $9.13B → $0 (-$9.13B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 325

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-329
Holders Change %
-99.7%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
325
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$923M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$848M
3
ACA
Avoro Capital Advisors
New York
-$688M
4
BlackRock
BlackRock
New York
-$684M
5
FCM
Farallon Capital Management
California
-$373M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
126
Citadel Advisors
Florida
– -$4.03M -23,399 Closed
DCM
127
Dupont Capital Management
Delaware
– -$3.99M -23,200 Closed
NRS
128
Neville Rodie & Shaw
New York
– -$3.95M -22,964 Closed
Walleye Capital
129
Walleye Capital
New York
– -$3.93K -22,854 Closed
HWAM
130
Hennion & Walsh Asset Management
New Jersey
– -$3.9M -22,685 Closed
BBA
131
Baker Bros. Advisors
New York
– -$3.86M -22,430 Closed
HI
132
Handelsinvest Investeringsforvaltning
Denmark
– -$3.79M -22,000 Closed
YCM
133
Yakira Capital Management
Connecticut
– -$3.74M -21,750 Closed
EAM
134
Erste Asset Management
Austria
– -$3.79M -21,600 Closed
EWM
135
Evercore Wealth Management
New York
– -$3.65M -21,207 Closed
Group One Trading
136
Group One Trading
Illinois
– -$3.61M -21,002 Closed
Allianz Asset Management
137
Allianz Asset Management
Germany
– -$3.61M -20,995 Closed
MOACM
138
Mutual of America Capital Management
New York
– -$3.55M -20,628 Closed
KCM
139
Kennedy Capital Management
Missouri
– -$3.51M -20,408 Closed
GC
140
Guggenheim Capital
Illinois
– -$3.45M -20,052 Closed
C
141
Chescapmanager
Maryland
– -$3.44M -20,000 Closed
Hudson Bay Capital Management
142
Hudson Bay Capital Management
Connecticut
– -$3.44M -20,000 Closed
CAM
143
ClariVest Asset Management
California
– -$3.4M -19,760 Closed
E
144
Ergoteles
New York
– -$3.36M -19,500 Closed
State of Wisconsin Investment Board
145
State of Wisconsin Investment Board
Wisconsin
– -$3.32M -19,306 Closed
FCMI
146
Foresite Capital Management I
California
– -$3.29M -19,100 Closed
Treasurer of the State of North Carolina
147
Treasurer of the State of North Carolina
North Carolina
– -$3.27M -18,999 Closed
Nordea Investment Management
148
Nordea Investment Management
Sweden
– -$3.29M -18,848 Closed
Envestnet Asset Management
149
Envestnet Asset Management
Illinois
– -$3.17M -18,412 Closed
Ameriprise
150
Ameriprise
Minnesota
– -$3M -17,396 Closed
4 5
6
7 8

XLRN Hedge Fund Activity: Q4 2021 in Review

1 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2021, worth a combined $0 — down 100% from $9.13B a quarter earlier.

Sellers outnumbered buyers: 325 funds closed out of XLRN and 0 opened new positions — a net loss of 325 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $923M sold.

  • 1 institutional investor held Acceleron Pharma (XLRN) as of Q4 2021, down from 330 in Q3 2021.
  • Funds reported $0 of Acceleron Pharma stock for Q4 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Acceleron Pharma positions in Q4 2021 and 325 closed out, a net change of -325 holders.
  • The largest Acceleron Pharma seller in Q4 2021 was T. Rowe Price Associates, an estimated $923M sold.

Based on aggregated 13F filings for Q4 2021.